Proteomic analysis of extracellular vesicle cargoes mirror the cardioprotective effects of rivaroxaban in patients with venous thromboembolism
PROTEOMICS – Clinical Applications · 2024
DOI: 10.1002/prca.202300014 ↗Kurz gefasst
Fachartikel in der Zeitschrift PROTEOMICS – Clinical Applications, 2024. Verfasst von Luisa Weiss und 12 weiteren Autor:innen. Beteiligte Einrichtung: UCD Conway SPHERE Research group, Conway Institute, University College Dublin, Dublin, Ireland. Hauptthemen laut MEDLINE: Rivaroxaban, Venous Thromboembolism, Extracellular Vesicles, Proteomics. Die Arbeit wurde bisher 9-mal zitiert (Crossref) und nennt 64 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Bayer.
Themen: Thromboseprophylaxe
Abstract (Originalsprache)
Background
Venous thromboembolism (VTE) remains a significant cause of morbidity and mortality worldwide. Rivaroxaban, a direct oral factor Xa inhibitor, mediates anti‐inflammatory and cardiovascular‐protective effects besides its well‐established anticoagulant properties; yet, these remain poorly characterized. Extracellular vesicles (EVs) are considered proinflammatory messengers regulating a myriad of (patho)physiological processes and may be highly relevant to the pathophysiology of VTE. The effects of Rivaroxaban on circulating EVs in VTE patients remain unknown. We have established that differential EV biosignatures are found in patients with non‐valvular atrial fibrillation anticoagulated with Rivaroxaban versus warfarin. Here, we investigated whether differential proteomic profiles of circulating EVs could also be found in patients with VTE. Methods and Results We performed comparative label‐free quantitative proteomic profiling of enriched plasma EVs from VTE patients anticoagulated with either Rivaroxaban or warfarin using a tandem mass spectrometry approach. Of the 182 quantified proteins, six were found to be either exclusive to, or enriched in, Rivaroxaban‐treated patients. Intriguingly, these proteins are involved in negative feedback regulation of inflammatory and coagulation pathways, suggesting that EV proteomic signatures may reflect both Rivaroxaban's anti‐coagulatory and anti‐inflammatory potential.
Conclusions
These differences suggest Rivaroxaban may have pleiotropic effects, supporting the reports of its emerging anti‐inflammatory and cardiovascular‐protective characteristics relative to warfarin.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- UCD Conway SPHERE Research group, Conway Institute, University College Dublin, Dublin, Ireland.
- School of Biomolecular and Biomedical Science, University College Dublin, Dublin, Ireland.
- Department of Haematology, Mater Misericordiae University Hospital, Dublin, Ireland.
- Department of Stroke Medicine, Mater Misericordiae University Hospital, Dublin, Ireland.
- School of Medicine, Royal College of Surgeons in Ireland, Dublin, Ireland.
ORCID-Profile: Luisa Weiss, Patricia B Maguire
Förderung
- Bayer
Zitieren
APA
Weiss, L., Uhrig, W., Kelliher, S., Szklanna, P. B., Prendiville, T., Comer, S. P., Edebiri, O., Egan, K., Lennon, Á., Kevane, B., Murphy, S., Ní Áinle, F., & Maguire, P. B. (2024). Proteomic analysis of extracellular vesicle cargoes mirror the cardioprotective effects of rivaroxaban in patients with venous thromboembolism. PROTEOMICS – Clinical Applications. https://doi.org/10.1002/prca.202300014
Vancouver
Weiss L, Uhrig W, Kelliher S, Szklanna PB, Prendiville T, Comer SP, et al. Proteomic analysis of extracellular vesicle cargoes mirror the cardioprotective effects of rivaroxaban in patients with venous thromboembolism. PROTEOMICS – Clinical Applications. 2024. doi:10.1002/prca.202300014
BibTeX
@article{Weiss2024,
author = {Weiss, Luisa and Uhrig, Wido and Kelliher, Sarah and Szklanna, Paulina B and Prendiville, Tadhg and Comer, Shane P and Edebiri, Osasere and Egan, Karl and Lennon, Áine and Kevane, Barry and Murphy, Sean and Ní Áinle, Fionnuala and Maguire, Patricia B},
title = {Proteomic analysis of extracellular vesicle cargoes mirror the cardioprotective effects of rivaroxaban in patients with venous thromboembolism},
journal = {PROTEOMICS – Clinical Applications},
year = {2024},
doi = {10.1002/prca.202300014}
}
EUVIMED